



**15 & 16 January 2018**

**PARIS** - Palais des Congrès

Organised by Pr Patrick Marcellin, APHC

**[www.aphc.info](http://www.aphc.info)**

Nash, HCC, viral hepatitis...

## **LUNCH WORKSHOP**

16th January from 12:30 to 14:30

### **New therapeutic strategies in HBV patients**

Chairs:


Massimo Levrero and Thomas Berg

Speakers:

Philippe Halfon and Maria Buti

# Definition of cure

Can treatment achieve what is not accomplished by nature ?



## « Functional cure »

- Antiviral treatment can be stopped with a minimal residual risk of viral reactivation
- HBsAg loss and anti-HBs seroconversion
- Inactivation and/or control of cccDNA by host-related factors

## « Partial cure »

- sustained suppression of HBV replication off treatment but persistent presence of HBsAg

## « Complete cure »

- HBsAg clearance and cccDNA eradication


The impact of molecular alterations and **viral DNA integration in infected** hepatocytes must be evaluated

In all cases *HBV cure* must be associated with a **clinical benefit** (disease progression and HCC)

## Unmet need

**Surrogate biomarkers of cccDNA activity (qHBsAg, HBcrAg, circulating HBV-RNAs)**

# Therapeutic targets



Nucleos(t)ide analogues

Peg IFN

## PEG-IFN + NAs PEG-IFN “add-on” on NAs Stop-NUCs

